Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. / Christensen, Hanna B; Gloriam, David E; Pedersen, Daniel Sejer; Cowland, Jack B; Borregaard, Niels; Bräuner-Osborne, Hans.

In: Journal of Pharmacological and Toxicological Methods, Vol. 88, No. Pt 1, 15.07.2017, p. 72-78.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Christensen, HB, Gloriam, DE, Pedersen, DS, Cowland, JB, Borregaard, N & Bräuner-Osborne, H 2017, 'Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils', Journal of Pharmacological and Toxicological Methods, vol. 88, no. Pt 1, pp. 72-78. https://doi.org/10.1016/j.vascn.2017.07.003

APA

Christensen, H. B., Gloriam, D. E., Pedersen, D. S., Cowland, J. B., Borregaard, N., & Bräuner-Osborne, H. (2017). Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. Journal of Pharmacological and Toxicological Methods, 88(Pt 1), 72-78. https://doi.org/10.1016/j.vascn.2017.07.003

Vancouver

Christensen HB, Gloriam DE, Pedersen DS, Cowland JB, Borregaard N, Bräuner-Osborne H. Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. Journal of Pharmacological and Toxicological Methods. 2017 Jul 15;88(Pt 1):72-78. https://doi.org/10.1016/j.vascn.2017.07.003

Author

Christensen, Hanna B ; Gloriam, David E ; Pedersen, Daniel Sejer ; Cowland, Jack B ; Borregaard, Niels ; Bräuner-Osborne, Hans. / Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. In: Journal of Pharmacological and Toxicological Methods. 2017 ; Vol. 88, No. Pt 1. pp. 72-78.

Bibtex

@article{70b0f61ab02c4919b7b4f1501707b8a0,
title = "Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils",
abstract = "INTRODUCTION: The label-free dynamic mass redistribution-based assay (DMR) is a powerful method for studying signalling pathways of G protein-coupled receptors (GPCRs). Herein we present the label-free DMR assay as a robust readout for pharmacological characterization of formyl peptide receptors (FPRs) in human neutrophils.METHODS: Neutrophils were isolated from fresh human blood and their responses to FPR1 and FPR2 agonists, i.e. compound 43, fMLF and WKYMVm were measured in a label-free DMR assay using Epic Benchtop System from Corning{\textregistered}. Obtained DMR traces were used to calculate agonist potencies.RESULTS: The potencies (pEC50) of fMLF, WKYMVm and compound 43, determined on human neutrophils using the label-free DMR assay were 8.63, 7.76 and 5.92, respectively. The DMR response to fMLF, but not WKYMVm and compound 43 could be blocked by the FPR1-specific antagonist cyclosporin H.DISCUSSION: We conclude that the DMR assay can be used, and complements more traditional methods, to study the signalling and pharmacology of endogenous FPR receptors in human neutrophils.",
keywords = "Journal Article",
author = "Christensen, {Hanna B} and Gloriam, {David E} and Pedersen, {Daniel Sejer} and Cowland, {Jack B} and Niels Borregaard and Hans Br{\"a}uner-Osborne",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2017",
month = jul,
day = "15",
doi = "10.1016/j.vascn.2017.07.003",
language = "English",
volume = "88",
pages = "72--78",
journal = "Journal of Pharmacological and Toxicological Methods",
issn = "1056-8719",
publisher = "Elsevier",
number = "Pt 1",

}

RIS

TY - JOUR

T1 - Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils

AU - Christensen, Hanna B

AU - Gloriam, David E

AU - Pedersen, Daniel Sejer

AU - Cowland, Jack B

AU - Borregaard, Niels

AU - Bräuner-Osborne, Hans

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2017/7/15

Y1 - 2017/7/15

N2 - INTRODUCTION: The label-free dynamic mass redistribution-based assay (DMR) is a powerful method for studying signalling pathways of G protein-coupled receptors (GPCRs). Herein we present the label-free DMR assay as a robust readout for pharmacological characterization of formyl peptide receptors (FPRs) in human neutrophils.METHODS: Neutrophils were isolated from fresh human blood and their responses to FPR1 and FPR2 agonists, i.e. compound 43, fMLF and WKYMVm were measured in a label-free DMR assay using Epic Benchtop System from Corning®. Obtained DMR traces were used to calculate agonist potencies.RESULTS: The potencies (pEC50) of fMLF, WKYMVm and compound 43, determined on human neutrophils using the label-free DMR assay were 8.63, 7.76 and 5.92, respectively. The DMR response to fMLF, but not WKYMVm and compound 43 could be blocked by the FPR1-specific antagonist cyclosporin H.DISCUSSION: We conclude that the DMR assay can be used, and complements more traditional methods, to study the signalling and pharmacology of endogenous FPR receptors in human neutrophils.

AB - INTRODUCTION: The label-free dynamic mass redistribution-based assay (DMR) is a powerful method for studying signalling pathways of G protein-coupled receptors (GPCRs). Herein we present the label-free DMR assay as a robust readout for pharmacological characterization of formyl peptide receptors (FPRs) in human neutrophils.METHODS: Neutrophils were isolated from fresh human blood and their responses to FPR1 and FPR2 agonists, i.e. compound 43, fMLF and WKYMVm were measured in a label-free DMR assay using Epic Benchtop System from Corning®. Obtained DMR traces were used to calculate agonist potencies.RESULTS: The potencies (pEC50) of fMLF, WKYMVm and compound 43, determined on human neutrophils using the label-free DMR assay were 8.63, 7.76 and 5.92, respectively. The DMR response to fMLF, but not WKYMVm and compound 43 could be blocked by the FPR1-specific antagonist cyclosporin H.DISCUSSION: We conclude that the DMR assay can be used, and complements more traditional methods, to study the signalling and pharmacology of endogenous FPR receptors in human neutrophils.

KW - Journal Article

U2 - 10.1016/j.vascn.2017.07.003

DO - 10.1016/j.vascn.2017.07.003

M3 - Journal article

C2 - 28716665

VL - 88

SP - 72

EP - 78

JO - Journal of Pharmacological and Toxicological Methods

JF - Journal of Pharmacological and Toxicological Methods

SN - 1056-8719

IS - Pt 1

ER -

ID: 181769649